A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
Phase 3
180
about 2.1 years
0.25–1.91666666666667
38 sites in AL, AR, CA +21
What this study is about
Researchers are testing the safety and effectiveness of tapinarof cream, a topical treatment, for children aged 3 months to under 2 years with atopic dermatitis. The trial will last approximately 761 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Tapinarof cream, 1%
- 2.Take Vehicle Cream
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
DERMATOLOGICALS
topical
Secondary: Investigator-assessed Local Tolerability Scale (LTS) scores by visit (overall), Investigator-assessed Local Tolerability Scale (LTS) scores by visit (sensitive areas), Number of participants with one or more Treatment Emergent Adverse Events (TEAEs), Percentage of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Dermatology